Oragenics Inc. · AMEX:OGEN
Oragenics — Investor Presentation (April 2023)
14 slides from Oragenics's investor presentation, Apr 3, 2023
Slide 1: Corporate Presentation
‘Corporate Presentation
Slide 2: Forward-Looking Statements
Looking Statements This communication contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management's beliefs and assumptions and information currently avai
Slide 3: Investment Highlights
nvestment Highlights : Kim Murphy, CEO i D> >25 years’ exp. leading vaccine franchises at GSK, Merck and Novartis years’ exp. leading TOC REE CGT M ~ Executed multiple successful commercial launches DD danet Huffman, cro ii > > 12 years experience at public and private healthcare co.’s > Significant
Slide 4: Intranasal Lead Asset: NT-CoV2-1
Intrana Lead Asset: NT-CoV2-1 + Licensed from NIH — two-proline substitution of SARS-CoV-2 spike protein Y Completed pivotal toxicology study in Dec. '22 confirming safety and immunogenicity profile to support IND submission + NT-CoV2-1 Non-Viral Intranasal Vaccine Differentiation and Advantages — P
Slide 5: Combines Four Technologies
1,Combines Fou r Technoloc * Licensed "2P" spike ‘National institute of protein design NIH) Allergy and + Highly de-risked Infectious Diseases (Pfizer/BioNTech, Moderna) + Patient-friendly + Potential to @ reduce infection and transmission + Sequence -> Ph1 GMP DS in 12 wks Netonalle h i lational Re
Slide 6: Improvements made during GSK ownership to make more soluble
Improvements made during GSK ownership to make more soluble Derencent MEDIATED . STATON ¥ V2 (80x00) we \VACCINE FORMULATED BY Area sg wr ange wate Suumib no ReNOMNG Neisseria cer gy) Gskde-prontized meningitidis Name ‘their flu vaccine programs in 2008 PROTEOSOMES (BDX200) and BDX300 did not COuTER
Slide 7: Anti-Spike IgG Titers Post-Dose
Day 20 Post-Dose 1 Day 35, 2 Weeks Post-Dose 2 10°. 405. Ce a Oo! 28 104 PE 104. xe 0882 xs 3510 88, BE aw § § 10 oo gg te a Be0 Bs ao 2S 102 ° S 102 ao aT 101 apn ep 10° caso Veh. BDX301 BDX301 BDX301 Veh. BDX301 BDX301 BDX301 Alone 45g +1519 Alone +5ug +15 ug Ag Ag Ag Ag “Anti-Spike IgG titers ind
Slide 8: Viral Titer
Viral Titer Lungs Nasal Turbinates 7 anes 7 tee = = A 5° go] aa gS a ES rN Bs 24. a 5 FS "| 4444 9090 = 3 a 3 o 2 2 = S 2 2 2 8 8 o4 o4 0. EE CSREES 0. te EEE $n Veh. BDX301 BDX301 BDX301 Veh. BDX301 BDX301 BDX301 Alone +5yg +15 yg Alone +5yg +15 ug Ag Ag Ag Efficacy of SmT1v3 and BDX301 formulation
Slide 9: Intranasal vaccines may address limitations of current vaccines
Intranasal vaccines may address limitations of current vaccines — Waning efficacy requiring third (and fourth) doses for new variants of concern (VOC) — Transmission remains a concern due to high nasopharyngeal viral loads + Recent study in healthcare workers in Israel during Omicron VOC shows limit
Slide 10: Intranasal vaccine competitive landscape
Live attenuated Phase 3 Hard to establish safety of live, iid Uerunabvaieters SARS-CoV-2 virus (WHO study ex-US)__attenuated SARS-CoV-2 vaccine mSeaNaccney juspmeaniete Live respiratory syncytial ppg Need to establish safety virus vector of new viral vector Blue Lake Biotech/ Live parainfluenza-5 vi
Slide 11: Complete NT-CoV2-1 formulation optimization; path to Phase 1
Q Complete NT-CoV2-1 formulation optimization Prepare US FDA and Canadian CTA regulatory strategies. | ‘Ongoing business development goal is to ) partner post-Phase 1 ¥ Final toxicology data release Q Submit IND O Initiate Phase 1 first-in-human NT-CoV2-1 clinical study
Slide 12: New Management Objectives
New.Management Objectives ildin hol Through the synergistic execution of new management objectives 1. Communicating and Achieving Milestone Timelines shia 2. Secure Capitalization for Sustained Operations 3. Building Visibility & Credibility Opportunistic Business it Model 1. Capital Markets 1. Secu
Slide 13: Investment Highlights and Near-Term Milestones
nvestment Highlights : Kim Murphy, CEO i D> >25 years’ exp. leading vaccine franchises at GSK, Merck and Novartis years’ exp. leading TOC REE CGT M ~ Executed multiple successful commercial launches DD danet Huffman, cro ii > > 12 years experience at public and private healthcare co.’s > Significant
Slide 14: Corporate and Investor Contacts
Corporat Investors: Janet-Huffman x Tirth T. Patel Chief Financial Officer \ LHA Investor Relations A 813.286.7900 ext. 246 | jhuffman@oragenics.com 212.201.6614 | tpatel@lhai.com \ NYSE American: OGEN